ProMIS Neurosciences (NASDAQ: PMN) back in Nasdaq bid price compliance

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq notified the company in writing that it now meets the $1.00 per share bid price rule and that the matter is closed.

The company had previously received a deficiency notice on January 8, 2025 after its common shares traded below $1.00 for 30 consecutive business days and was given up to two 180-day grace periods, extending to December 29, 2025. Its closing bid price was at least $1.00 for 10 consecutive business days from November 28, 2025 to December 11, 2025, which restored compliance with the bid price rule.

Positive

• ProMIS Neurosciences Inc. regained compliance with Nasdaq’s $1.00 minimum bid price rule, closing a prior deficiency matter and removing near-term delisting risk tied to bid price.

Negative

• None.

Insights

Equity markets analyst

Regaining Nasdaq bid-price compliance removes a key listing overhang for ProMIS.

ProMIS Neurosciences Inc. received confirmation from Nasdaq that it now complies with the minimum $1.00 bid price requirement for continued trading on the Nasdaq Capital Market. This follows an earlier deficiency notice on January 8, 2025 and an extended grace period that ran until December 29, 2025.

The company achieved compliance after its common shares closed at or above $1.00 for 10 consecutive business days from November 28, 2025 through December 11, 2025. This development means Nasdaq has closed the matter, indicating that, based on the information provided, the immediate risk of delisting related to the bid price rule has been addressed.

Future company disclosures will be important for understanding how it maintains trading levels above the minimum threshold and continues to meet other Nasdaq listing standards over time.

0001374339false00013743392025-12-122025-12-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

PROMIS NEUROSCIENCES INC.

(Exact name of registrant as specified in its charter)

​

Ontario, Canada	​ ​ ​	001-41429	​ ​ ​	98-0647155
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

​

Suite 200, 1920 Yonge Street, Toronto, Ontario	​ ​ ​		​ ​ ​	M4S 3E2
(Address of principal executive offices)				(Zip Code)

​

Registrant’s telephone number, including area code: (416) 847-6898

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of Each Exchange on Which Registered
Common Shares, no par value per share	​	PMN		The NASDAQ Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 8.01 Other Events.

​

On December 12, 2025, ProMIS Neurosciences Inc. (the “Company”) received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”) pursuant to NASDAQ Listing Rule 5550(a)(2) (“Bid Price Rule”) and that the matter is now closed.

​

As previously disclosed, on January 8, 2025, the Company received a deficiency letter from Nasdaq notifying the Company that, for the 30 consecutive business days prior to the date of the deficiency letter, the closing bid price for the Company’s common stock was trading below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant tothe Bid Price Rule. In accordance with Nasdaq rules, the Company was provided with an initial period of 180 calendar days, or until July 2, 2025, to regain compliance with the Bid Price Rule.

​

Subsequently, the Company was granted an additional 180-day grace period, until December 29, 2025, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company meeting the continued listing requirement for stockholder’s equity and all other initial listing standards for Nasdaq with the exception of the Bid Price Rule, and the Company’s provided written notice of its confirmation to cure the deficiency during the additional compliance period, including by effecting a reverse stock split, if necessary.

​

The closing bid price of the Company’s common shares has been $1.00 or greater for the 10 consecutive business days from November 28, 2025 to December 11, 2025. Accordingly, the Company has regained compliance with the Bid Price Rule.

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	PROMIS NEUROSCIENCES INC.
​	​	​
Date: December 16, 2025	By:	/s/ Neil Warma
​	​	Name: Neil Warma
​	​	Title: Chief Executive Officer

​

​

​

FAQ

What Nasdaq update did ProMIS Neurosciences (PMN) report?

ProMIS Neurosciences Inc. reported that Nasdaq notified the company it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market and that the matter is closed.

Why was ProMIS Neurosciences (PMN) previously out of compliance with Nasdaq rules?

On January 8, 2025, ProMIS Neurosciences received a deficiency letter from Nasdaq because its common shares had a closing bid price below $1.00 for 30 consecutive business days, violating Nasdaq’s minimum bid price rule.

How did ProMIS Neurosciences (PMN) regain compliance with the $1.00 bid price rule?

The company’s common shares had a closing bid price of at least $1.00 for 10 consecutive business days, from November 28, 2025 to December 11, 2025, which satisfied Nasdaq’s criteria to regain compliance with the bid price rule.

What grace periods did Nasdaq grant ProMIS Neurosciences (PMN) to fix the bid price issue?

Nasdaq initially gave ProMIS Neurosciences 180 calendar days, until July 2, 2025, to regain compliance, and later granted an additional 180-day grace period extending to December 29, 2025.

Did ProMIS Neurosciences (PMN) meet other Nasdaq listing standards during the deficiency period?

Yes. When granting the additional grace period, Nasdaq’s determination was based on ProMIS Neurosciences meeting the continued listing requirement for stockholder’s equity and all other initial listing standards except the minimum bid price rule.

Was a reverse stock split required for ProMIS Neurosciences (PMN) to regain Nasdaq compliance?

The company had indicated it could cure the deficiency, including by effecting a reverse stock split if necessary, but the update shows compliance was regained based on its bid price performance over 10 consecutive business days.